Drug intelligence / Profile preview

OTTx Peptide Candidate (Ocular)

Development stage: Preclinical
Lead developer: On Target Therapeutics
Modality: Peptides
Administration: Ophthalmic

Overview

OTTx Peptide Candidate (Ocular) is a preclinical-stage peptide modulator targeting an unspecified G protein-coupled receptor (GPCR) for the treatment of ocular inflammation and dry eye disease. Developed by On Target Therapeutics, the candidate utilizes a proprietary platform designed to engineer stable, long-acting peptides that overcome the typical pharmacokinetic limitations of native peptide ligands. By providing sustained modulation of GPCR signaling in the eye, the therapy aims to reduce inflammation and restore ocular surface homeostasis. The program is currently undergoing preclinical evaluation with the objective of advancing into early-phase clinical trials.

Other names: OTTx peptide candidate (ocular inflammation and dry eyes)

Beyond the preview

Go deeper on OTTx Peptide Candidate (Ocular).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTTx Peptide Candidate (Ocular).

Explore the full profile